Jennifer Kates:
So, if we think back to 2020, when COVID first was emerging and becoming a huge emergency, there were no vaccines. And the government made a bet that if it purchased vaccines and advanced candidates that weren't even authorized yet, and helped fund the research that one of those candidates would be good enough. And in fact, we had more than one, and the government continued to buy in bulk. And by doing so, the federal government basically was saying to the manufacturers, we're taking care of your risk here. We're buying these from you to distribute, so you don't have that risk of losing money in the marketplace.
Now, that we're going into a commercialized environment, it's the market. And these manufacturers are trying to assess who's going to want my vaccine, what are they — what's it going to be worth to them? Is there going to be demand? And they're just — they're going to try to make some profit. That's not how it worked before.
ncG1vNJzZmivp6x7sa7SZ6arn1%2Bjsri%2Fx6isq2ejnby4e9ahsGalkaPCp63CrayrnaKoeqK%2BxGafoqOZo7Rur86voJ1lppawpLXNnmSpqpmYsrQ%3D